UnitedHealth beats and raises as medical costs finally cool — long UNH as the defensive rotation target

Verdict: the turnaround is real enough to watch, not yet to buy

On the long-term thesis — a beaten-down UnitedHealth re-rating as earnings recover — the evidence is genuinely two-sided, and the horizon for judging it is the coming two earnings reports, not the next few sessions. The strongest support is cash generation: Q2 2026 free cash flow hit $10.3B, up 25.8% from Q1, with debt-to-equity falling from 0.75 to 0.70, so the recovery is being self-financed. The strongest counter is the profit line: net income fell 12.7% to $5.5B quarter over quarter, net margin compressed to 4.9% from 5.6%, and the provisional ownership filing for the period ended September 30, 2026 shows net insider open-market selling of roughly $661K — insiders are not yet acting like a recovery is certain. Meanwhile, the published entry rules have not fired (price sits about 2.6% above the $396.48 pullback line) and the strategy's historical performance could not be measured because raw and adjusted prices use inconsistent bases, so there is no measured historical evidence supporting the timing claim. Wait for either a confirmed pullback-reversal bar or a quarter of stabilizing margins before committing capital.

Trade now: UNH turnaround thesis is waiting on a pullback that hasn't arrived

The short answer: wait. The idea's business case is genuinely interesting — the thesis argues that UnitedHealth, a beaten-down mega-cap, could steadily re-rate as analysts upgrade estimates, with the defensive insurance profile providing shelter if money rotates out of AI-driven tech. And the latest fundamentals don't contradict that: Q2 revenue of $112.0B (up 0.3% from Q1) and free cash flow of $10.3B, up 25.8% quarter over quarter, with dividends per share of $8.85 paid over the trailing year and a 5.1% annual growth rate. But a good thesis is not a live entry. The strategy's entry requires price to dip to or below its 50-day trend line and then close back above it, with momentum confirming. Today's close was $406.97, about 2.6% above that $396.48 line — the pullback simply hasn't happened. One important honesty note: historical performance of this exact setup was not measured, because UNH's raw and adjusted price series sit on different bases, so a historical win rate for this setup cannot be quoted. This is a watch-list setup, not a proven signal. Horizon is a swing-to-position trade measured in weeks to about 90 trading days (the time exit). The pivotal condition is concrete: a daily bar whose low touches $396.48 or below but which closes above it, with RSI (a 0–100 momentum gauge) above 45, and the MACD momentum line making a fresh upward cross of its signal line. Note the MACD line is currently above its signal, so one ingredient — a fresh cross — would first require momentum to cool. The downside that matters: the two defined stops are a 2% loss cap on the position and a close below the second support level near $415.18, in practice meaning a break of the $399 support zone signals invalidation of the pullback-reversal read. Wait means: set alerts, do nothing until the bar forms. Also flag: the latest ownership filing (period ended 2026-09-30, provisional) shows net insider open-market selling of about $661K — a mild caution against chasing. ### Technical details Entry rule (UNH, daily bars), all four conditions on the same day: (1) the day's low at or below the EMA(50) — currently $396.48, so price must fall roughly $10.49 (about 2.6%) from the $406.97 close; (2) the day's close back above that EMA(50); (3) RSI(14) above 45 — currently 52.1, already satisfied; (4) MACD(12,26,9) line crossing above its signal line that day — currently the line sits above the signal at 7.23, so no cross is in place and a fresh crossover requires momentum to first dip and turn again. Exits, in priority order: 2% stop on unrealized loss; 4% take profit; MACD line falling below the signal line; a close below the second-ranked support level; and a hard 90-bar time exit. Nearest support is $399.10, nearest resistance $406.39 (observation time 2026-11-01 18:55 UTC). The defined 4% target against the 2% stop works out to a 2:1 reward-to-risk by construction, but no realistic target calculation is possible until the entry bar exists, since entry price is unknown today. Stop-loss and take-profit-by-level rules reference live support/resistance rankings, which shift with the chart — they will be re-read at trigger time.

A real cash-flow recovery is underway at UnitedHealth — the question is whether the trigger catches it

Takeaway: the bull thesis has genuine fundamental support — UnitedHealth's 2026 half shows sharp cash-generation recovery, a shrinking debt load, and revenue grinding higher — but this is a watch-list setup, because the published entry rules did not fire in the evaluated window and the strategy's history could not be measured. ### Cash generation has genuinely rebounded Free cash flow (operating cash flow minus capital spending) reached $10.25B in Q2 2026, up 25.8% from $8.15B in Q1, and operating cash flow rose 24.0% to $11.05B. The contrast with Q4 2025 — just $160M of free cash flow and $10M of net income on $113.2B of revenue — is stark. For a thesis…

Scores

• Conviction score breakdown: 44
• Thesis support: 55
• Trade readiness: 35
• Risk quality: 55
• Trigger proximity: 30
• Fundamentals trend: 45

Watch items

• UNH — Daily low vs EMA(50) at $396.48
• UNH — MACD(12,26,9) line vs signal line
• UNH — RSI (14)
• UNH — Nearest support level
• UNH — Next quarterly net margin
• UNH — Insider net open-market activity